Chlormethine Treatment Effectively Targets the Tumor Microenvironment in Early-stage Mycosis Fungoides patients
Abstract Topical chlormethine is an established skin-directed therapy for early-stage mycosis fungoides (MF), yet treatment response is heterogeneous and treatment-associated dermatitis is common, suggesting incompletely defined mechanisms within the tumor microenvironment (TME). We investigated how chlormethine remodels the MF TME and which baseline features associate with clinical response. In an exploratory, prospective, open-label study, 21 early-stage MF patients applied chlormethine gel for 16 weeks; 17 were analyzed. At baseline, paired lesional and non-lesional suction blister fluid and biopsies were collected; the same lesion was resampled after treatment, and electively during dermatitis. Healthy controls (n=10) provided baseline samples. Immune profiling integrated flow cytometry, targeted proteomics, imaging mass cytometry and TCRβ sequencing to characterize cellular, proteomic, and clonal dynamics. Chlormethine induced heterogeneous clinical improvement at week 16, and dermatitis duration correlated with response magnitude. Baseline analyses identified an immune-reactive TME in responders, enriched for activated cytotoxic T cells in lesional versus non-lesional skin. Dermatitis samples demonstrated activated immune infiltrates and proteomic signatures of inflammatory cell recruitment, marking a treatment-associated immune-activation phase followed by clonal and inflammatory contraction—including reductions in dominant T-cell clones, aberrant T cells, regulatory T cells, and immunosuppressive mediators. Longitudinal analyses indicates coordinated modulation of interferon pathways, cytotoxic effector signatures, and checkpoint signaling, identifying cytotoxic interferon-associated immunity as a principal driver of response. These findings support a biphasic mechanism of action—direct tumor cytotoxicity and immune-mediated TME remodeling—and provide rationale for immune-based stratification in early-stage MF. This trial was registered at www.clinicaltrials.gov as #NCT05303480 and EudraCT as #2021-001576-41.
Authors
- Marieke E. Ijsselsteijn (ORCID: https://orcid.org/0000-0002-8195-736X)
- Tessa Niemeyer‐van der Kolk (ORCID: https://orcid.org/0000-0002-3221-1609)
- Koen D. Quint (ORCID: https://orcid.org/0000-0002-3267-5630)
- Rianne Rijneveld
- Selinde S. Wind (ORCID: https://orcid.org/0000-0002-1064-4198)
- Roderick C. Slieker (ORCID: https://orcid.org/0000-0003-0961-9152)
- Willem H. Zoutman (ORCID: https://orcid.org/0000-0003-0085-3647)
- Ingrid Tomljanović (ORCID: https://orcid.org/0000-0002-3296-1856)
- Patty M. Jansen (ORCID: https://orcid.org/0000-0002-2361-9303)
- Hendrika W. Grievink (ORCID: https://orcid.org/0000-0002-5611-108X)
- Maarten H. Vermeer (ORCID: https://orcid.org/0000-0002-5872-4613)
- Veerle A. Merkus (ORCID: https://orcid.org/0000-0003-3982-2477)
- Mick van Schaick
- Yalcin Yavuz
- Robert Rißmann (ORCID: https://orcid.org/0000-0002-5867-9090)
- M.S.N.C. Florquin
- Manon Jansen
- Naomi Klarenbeek
- Rein Willemze
- Noel F.C. de Miranda
- Anne M.R. Schrader
Institutions
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- Centre for Human Drug Research (NL)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-16
- DOI
- https://doi.org/10.21203/rs.3.rs-11562688/v1
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- preprint